531 related articles for article (PubMed ID: 7019379)
1. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
[TBL] [Abstract][Full Text] [Related]
2. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
Gigli I; Sorvillo J; Halbwachs-Mecarelli L
J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
[TBL] [Abstract][Full Text] [Related]
3. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
Gigli I; Fujita T; Nussenzweig V
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
[TBL] [Abstract][Full Text] [Related]
5. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
6. C3 nephritic factor stabilization of the classic C3 convertase: a role for C2 in C3 nephritic factor activity.
McLean RH; Nilson SH
Proc Soc Exp Biol Med; 1979 Jul; 161(3):358-63. PubMed ID: 461464
[No Abstract] [Full Text] [Related]
7. Monoclonal anti-human C4b antibodies: stabilization and inhibition of the classical-pathway C3 convertase.
Ichihara C; Nakamura T; Nagasawa S; Koyama J
Mol Immunol; 1986 Feb; 23(2):151-7. PubMed ID: 2422544
[TBL] [Abstract][Full Text] [Related]
8. Localization of the covalent C3b-binding site on C4b within the complement classical pathway C5 convertase, C4b2a3b.
Kozono H; Kinoshita T; Kim YU; Takata-Kozono Y; Tsunasawa S; Sakiyama F; Takeda J; Hong K; Inoue K
J Biol Chem; 1990 Aug; 265(24):14444-9. PubMed ID: 2387864
[TBL] [Abstract][Full Text] [Related]
9. A model system for the study of the assembly and regulation of human complement C3 convertase (classical pathway).
Thielens NM; Colomb MG
Eur J Immunol; 1986 Jun; 16(6):617-22. PubMed ID: 3487454
[TBL] [Abstract][Full Text] [Related]
10. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
Ito S; Tamura N; Fujita T
Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
[TBL] [Abstract][Full Text] [Related]
11. Purification and characterization of the C3 convertase of the classical pathway of human complement system by size exclusion high-performance liquid chromatography.
Nagasawa S; Kobayashi C; Maki-Suzuki T; Yamashita N; Koyama J
J Biochem; 1985 Feb; 97(2):493-9. PubMed ID: 3874204
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus transformed B cell lines derived from patients with systemic lupus erythematosus produce a nephritic factor of the classical complement pathway.
Hiramatsu M; Tsokos GC
Clin Immunol Immunopathol; 1988 Jan; 46(1):91-9. PubMed ID: 2826058
[TBL] [Abstract][Full Text] [Related]
13. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
14. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.
Takata Y; Kinoshita T; Kozono H; Takeda J; Tanaka E; Hong K; Inoue K
J Exp Med; 1987 Jun; 165(6):1494-507. PubMed ID: 3495629
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME; Kinoshita T; Nussenzweig V
J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
[TBL] [Abstract][Full Text] [Related]
16. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
Pangburn MK
J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
[TBL] [Abstract][Full Text] [Related]
17. The human complement system: assembly of the classical pathway C3 convertase.
Kerr MA
Biochem J; 1980 Jul; 189(1):173-81. PubMed ID: 6906228
[TBL] [Abstract][Full Text] [Related]
18. Formation of high affinity C5 convertase of the classical pathway of complement.
Rawal N; Pangburn MK
J Biol Chem; 2003 Oct; 278(40):38476-83. PubMed ID: 12878586
[TBL] [Abstract][Full Text] [Related]
19. Complement receptor is an inhibitor of the complement cascade.
Iida K; Nussenzweig V
J Exp Med; 1981 May; 153(5):1138-50. PubMed ID: 6910481
[TBL] [Abstract][Full Text] [Related]
20. The effects of iodine and thiol-blocking reagents on complement component C2 and on the assembly of the classical-pathway C3 convertase.
Kerr MA; Parkes C
Biochem J; 1984 Apr; 219(2):391-9. PubMed ID: 6611150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
